Atrophic Papulosis: A Systematic Review of Pediatric Cases.
This systematic review of 36 reports describing 54 pediatric patients found that atrophic papulosis was usually classified as malignant, commonly involved the CNS and gastrointestinal tract, and often developed systemic manifestations within one year after cutaneous onset.
Open original publication →What the AI sees
This systematic review of 36 reports describing 54 pediatric patients found that atrophic papulosis was usually classified as malignant, commonly involved the CNS and gastrointestinal tract, and often developed systemic manifestations within one year after cutaneous onset.
Research significance
The review provides evidence supporting early recognition and longitudinal surveillance of pediatric atrophic papulosis; it is reasonable to hypothesize that risk-adapted monitoring could enable earlier management of systemic disease, but the record does not show that any treatment or surveillance strategy improves outcomes.
Source abstract
BACKGROUND: Atrophic papulosis is a rare occlusive vasculopathy that can present with isolated cutaneous disease or with systemic involvement. Pediatric cases are uncommon, and existing reports are heterogeneous, limiting understanding of disease patterns, timing of organ involvement, and outcomes. METHODS: A systematic literature search identified pediatric patients (< 18 years at symptom onset) diagnosed with atrophic papulosis. Case-level data were extracted where available. Patients were classified as benign atrophic papulosis (BAP) or malignant atrophic papulosis (MAP). Descriptive analyses were performed to summarize organ involvement, timing relative to cutaneous onset, multisystem disease patterns, treatments, and outcomes. RESULTS: Thirty-six reports describing 54 pediatric patients were identified. At the most recent follow-up, 8 patients (14.8%) were classified as BAP and 46 (85.2%) as MAP. Among MAP patients, central nervous system (CNS) involvement was most common (71.7%), followed by gastrointestinal involvement (67.4%). Multisystem extracutaneous disease occurred frequently (78.3%). Systemic involvement typically developed within the first year after the onset of cutaneous disease, although the interval varied substantially among patients. Treatment outcomes ranged from clinical stability to progressive multisystem disease and death. CONCLUSIONS: In pediatric patients, atrophic papulosis is often classified as malignant, with frequent CNS and gastrointestinal involvement. These findings underscore the need for early recognition and longitudinal follow-up.